Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 1
1984 1
1985 1
1986 1
1987 1
1988 3
1989 2
1990 1
1992 3
1993 4
1994 3
1995 1
1996 1
1997 1
1998 1
1999 4
2000 7
2001 1
2002 2
2003 1
2004 3
2005 2
2006 3
2007 2
2008 3
2009 6
2010 5
2011 5
2012 4
2013 1
2014 3
2015 2
2016 1
2017 1
2018 2
2020 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Chronic myeloid leukemia in Asia.
Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, Kweon IY, O'Neil WM, Saikia TK, Wang J. Au WY, et al. Among authors: jootar s. Int J Hematol. 2009 Jan;89(1):14-23. doi: 10.1007/s12185-008-0230-0. Epub 2008 Dec 20. Int J Hematol. 2009. PMID: 19101781 Review.
Amifostine and hematologic effects.
Sriswasdi C, Jootar S, Giles FJ. Sriswasdi C, et al. Among authors: jootar s. J Med Assoc Thai. 2000 Apr;83(4):374-82. J Med Assoc Thai. 2000. PMID: 10808697 Review.
CML treatment in Asia-Pacific region.
Jootar S. Jootar S. Hematology. 2012 Apr;17 Suppl 1:S72-4. doi: 10.1179/102453312X13336169155772. Hematology. 2012. PMID: 22507785 Free article.
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
Do YR, Kwak JY, Kim JA, Kim HJ, Chung JS, Shin HJ, Kim SH, Bunworasate U, Choi CW, Zang DY, Oh SJ, Jootar S, Reksodiputro AH, Lee WS, Mun YC, Kong JH, Caguioa PB, Kim H, Park J, Kim DW. Do YR, et al. Among authors: jootar s. Br J Haematol. 2020 Apr;189(2):303-312. doi: 10.1111/bjh.16381. Epub 2020 Feb 3. Br J Haematol. 2020. PMID: 32012231 Free PMC article. Clinical Trial.
A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study.
Giles FJ, Shan J, Advani SH, Akan H, Aydogdu I, Aziz Z, Azim HA, Bapsy PP, Buyukkececi F, Chaimongkol B, Chen PM, Cheong SK, Ferhanoglu B, Hamza R, Khalid HM, Intragumtornchai T, Kim SW, Kim SY, Koc H, Kumar L, Kumar R, Lei KI, Lekhakula A, Muthalib A, Patel M, Poovalingam VP, Prayoonwiwat W, Rana F, Reksodiputro AH, Ruff P, Sagar TG, Schwarer AP, Song HS, Suh CW, Suharti C, Supindiman I, Tee GY, Thamprasit T, Villalon AH, Wickham NR, Wong JE, Yalcin A, Jootar S; International Oncology Study Group NHL1 Study. Giles FJ, et al. Among authors: jootar s. Leuk Lymphoma. 2000 Dec;40(1-2):95-103. doi: 10.3109/10428190009054885. Leuk Lymphoma. 2000. PMID: 11426633 Clinical Trial.
Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies.
Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, Susantitaphong P, Katavetin P, Kanjanabuch T, Avihingsanon Y, Eiam-Ong S. Praditpornsilpa K, et al. Among authors: jootar s. Kidney Int. 2011 Jul;80(1):88-92. doi: 10.1038/ki.2011.68. Epub 2011 Mar 23. Kidney Int. 2011. PMID: 21430643 Free article.
Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia.
Kim H, Kim S, Kim HJ, Kim YK, Kwak JY, Yhim HY, Kim SH, Do YR, Oh S, Lee SE, Jootar S, Cui JW, Kim DW. Kim H, et al. Among authors: jootar s. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e391-e399. doi: 10.1016/j.clml.2018.06.031. Epub 2018 Jul 4. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30082224 Free article.
Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.
Lee SE, Choi SY, Kim SH, Jootar S, Kim HJ, Sohn SK, Park JS, Kim SH, Zang DY, Oh SJ, Kim DW. Lee SE, et al. Among authors: jootar s. Leuk Res. 2018 Jul;70:100-105. doi: 10.1016/j.leukres.2018.06.002. Epub 2018 Jun 7. Leuk Res. 2018. PMID: 29908417 Clinical Trial.
79 results